Tofacitinib as an alternative therapy for refractory intestinal Behçet’s syndrome
Background: Intestinal Behçet’s syndrome is a major cause of morbidity and mortality in Behçet’s syndrome. Objectives: Current treatment challenges remain in refractory intestinal Behçet’s syndrome, when patients failed first and second-line therapies. Design: We reported the efficacy and safety pro...
| Published in: | Therapeutic Advances in Musculoskeletal Disease |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2022-09-01
|
| Online Access: | https://doi.org/10.1177/1759720X221124014 |